WILMINGTON, N.C. & MARIETTA, Ga.--(BUSINESS WIRE)--Osmotica Pharmaceutical Corp. today announced the appointment of Gene Wright, Pharm.D., Ph.D. as Vice President, Head of Global Clinical Development. In his role, Dr. Wright will serve as a key member of the senior leadership team at Osmotica Pharmaceutical, where he is responsible for leading the global clinical development strategy and execution for the company’s development programs. Praveen Tyle, Ph.D., President and CEO of Osmotica Pharmaceutical stated, “We are very pleased to have Gene as part of our senior leadership team. Gene will play an integral role in the success of our organization as we continue to bring innovated products to the marketplace, especially as we devote more resources towards novel drug development programs.”
Dr. Wright has over 25 years of pharmaceutical industry experience in early and late stage global clinical development programs in CNS, pain, rheumatoid arthritis and infectious disease. Prior to joining Osmotica Pharmaceutical, he was Senior Vice President of Clinical Development at Zalicus Inc., which was formed through the merger of CombinatoRx, Inc. and Neuromed Pharmaceuticals. At Zalicus, he was responsible for the development programs in pain and inflammation. Prior to joining Neuromed, Dr. Wright worked for Schering-Plough Corporation as Executive Director and Senior Project Leader of the Antiviral/Antifungal groups. He also worked as Vice President of CNS/Pain Development, Project Management and Pharmacokinetics at Biovail Technologies and at Pharmacia.
Dr. Wright earned his doctor of pharmacy from the University of the Pacific in Stockton, CA, master’s degree in business administration from National University in San Diego and a doctor of philosophy in Pharmaceutical Sciences from the University of Kentucky.
About Osmotica Pharmaceutical
Osmotica Pharmaceutical is a global specialty pharmaceutical company with a proven history of developing commercially successful pharmaceutical products. The company uses its proprietary osmotic technology platform and with strategic partners develops and commercializes high quality pharmaceutical products. In addition to the products currently on the market, the company’s pipeline includes numerous ANDA programs and several innovative neurology-based NDA programs.
Osmotica Pharmaceutical and its related companies form an international group of companies with principal operations located in the United States, Argentina and Hungary.
For more information on the Company, please visit Osmotica’s website at www.osmotica.com. This press release is directed to residents of the United States.
